Wuhan Hvsen Biotechnology Co Ltd (300871) - Total Assets
Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) holds total assets worth CN¥2.96 Billion CNY (≈ $432.85 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 300871 net asset value for net asset value and shareholders' equity analysis.
Wuhan Hvsen Biotechnology Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data.
Wuhan Hvsen Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Wuhan Hvsen Biotechnology Co Ltd's total assets of CN¥2.96 Billion consist of 43.5% current assets and 56.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.8% |
| Accounts Receivable | CN¥454.36 Million | 15.1% |
| Inventory | CN¥248.16 Million | 8.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥114.44 Million | 3.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300871 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wuhan Hvsen Biotechnology Co Ltd's current assets represent 43.5% of total assets in 2024, a decrease from 53.4% in 2016.
- Cash Position: Cash and equivalents constituted 10.8% of total assets in 2024, down from 20.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 11.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 15.1% of total assets.
Wuhan Hvsen Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Wuhan Hvsen Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Wuhan Hvsen Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.70 | 1.35 | 3.48 |
| Quick Ratio | 1.36 | 1.07 | 3.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥525.17 Million | CN¥316.18 Million | CN¥838.48 Million |
Wuhan Hvsen Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Wuhan Hvsen Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.57 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | CN¥3.01 Billion |
| Market Capitalization | $778.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wuhan Hvsen Biotechnology Co Ltd's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Wuhan Hvsen Biotechnology Co Ltd's assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Wuhan Hvsen Biotechnology Co Ltd (2016–2024)
The table below shows the annual total assets of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.01 Billion ≈ $441.14 Million |
+1.32% |
| 2023-12-31 | CN¥2.98 Billion ≈ $435.40 Million |
-0.46% |
| 2022-12-31 | CN¥2.99 Billion ≈ $437.40 Million |
+9.03% |
| 2021-12-31 | CN¥2.74 Billion ≈ $401.19 Million |
+56.47% |
| 2020-12-31 | CN¥1.75 Billion ≈ $256.41 Million |
+169.54% |
| 2019-12-31 | CN¥650.08 Million ≈ $95.13 Million |
+39.32% |
| 2018-12-31 | CN¥466.60 Million ≈ $68.28 Million |
+35.57% |
| 2017-12-31 | CN¥344.18 Million ≈ $50.36 Million |
+34.52% |
| 2016-12-31 | CN¥255.86 Million ≈ $37.44 Million |
-- |
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various vet… Read more